Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin
Open Access
Abstract
Cantharidin (CTD) is the main active ingredient isolated from Mylabris, and norcantharidin (NCTD) is a demethylated derivative of CTD, which has similar antitumor activity to CTD and lower toxicity than CTD. However, the clinical use of NCTD is limited due to its poor solubility, low bioavailability, and toxic effects on normal cells. To overcome these shortcomings, researchers have explored a number of strategies, such as chemical structural modifications, microsphere dispersion systems, and nanodrug delivery systems. This review summarizes the structure–activity relationship of NCTD and novel strategies to improve the solubility and bioavailability of NCTD as well as reduce the toxicity. This review can provide evidence for further research of NCTD.Keywords
Funding Information
- Shandong Provincial Natural Science Foundation, China (ZR2022MH173, 202113020512)
- Medical and Health Science and Technology Development Plan of Shandong Province, China (ZR2022MH173, 202113020512)
This publication has 135 references indexed in Scilit:
- Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cellsDrug Design, Development and Therapy, 2013
- Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorptionInternational Journal of Nanomedicine, 2012
- Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MSInternational Journal of Nanomedicine, 2012
- Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activityBioorganic & Medicinal Chemistry, 2011
- Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted deliveryNanomedicine: Nanotechnology, Biology and Medicine, 2010
- Targeting of the B-lineage leukemia stem cells and their progeny with norcantharidin encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8in vitroJournal of Drug Targeting, 2010
- Structure-Activity Relationship Studies of Fostriecin, Cytostatin, and Key Analogs, with PP1, PP2A, PP5, and (β12–β13)-Chimeras (PP1/PP2A and PP5/PP2A), Provide Further Insight into the Inhibitory Actions of Fostriecin Family InhibitorsThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effectLife Sciences, 2009
- Antibody-modified liposomes for cancer chemotherapyExpert Opinion on Drug Delivery, 2008
- Formulation, preparation and evaluation of flunarizine-loaded lipid microspheresJournal of Pharmacy and Pharmacology, 2007